Category

Archives

ERK

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer

42 views | Apr 27 2022

Kiran Kundu et al. provided a rationale for lurbinectedin in combination with ATR inhibitors to overcome resistance in SCLC with low SLFN11 expression. [Read the Full Post]

IL4/IL4R signaling promotes the osteolysis in metastatic bone of CRC through regulating the proliferation of osteoclast precursors

155 views | Dec 07 2021

Qian Jin et al. thought that ravoxertinib could be a new therapeutical target for bone metastasis of CRC. [Read the Full Post]

Genetic Prioritization, Therapeutic Repositioning and Cross-Disease Comparisons Reveal Inflammatory Targets Tractable for Kidney Stone Disease

238 views | Oct 09 2021

Hai Fang et al. provided the rich information of how to target innate immune pathways, with the potential of advancing immunotherapeutic strategies for nephrolithiasis. [Read the Full Post]

Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma

220 views | Oct 08 2021

Ruchi P Patel et al. found that romidepsin in combination with mTOR inhibition could be an effective treatment strategy against uveal melanoma due in part to changes in apoptotic proteins. [Read the Full Post]

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

880 views | Jul 27 2021

Marta Krejci et al. found that the course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths. [Read the Full Post]

Targeting ERK combined with apatinib may be a promising therapeutic strategy for treating oral squamous cell carcinoma

314 views | Jul 14 2021

Tong-Chao Zhao et al. suggested that the combination of apatinib and SCH772984 was a potent OSCC therapy. [Read the Full Post]

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

670 views | Jun 02 2021

Mark R Middleton et al. found that Berzosertib + gemcitabine was well tolerated in patients with advanced solid tumours and showed preliminary efficacy signs. [Read the Full Post]

A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

266 views | Dec 19 2020

Colin Weekes et al. thought that overlapping AEs and cumulative toxicity could not be adequately managed on either dosing schedule, restricting the ability to further develop this combination. [Read the Full Post]

Inhibition of the ERK/RSK kinase cascade limits Chlamydia trachomatis infection

340 views | Oct 04 2020

Yaohua Xue et al. demonstrated not only that the ERK/RSK pathway played a critical role in Chlamydia infection, but also that these kinases had potential as targets for host-directed therapy against Chlamydia trachomatis. [Read the Full Post]

NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma

317 views | Oct 04 2020

Ivette Valencia-Sama et al. suggested that conventional therapy-resistant, relapsed neuroblastoma might be effectively treated via combined inhibition of SHP2 and MEK or ERK of the RAS-MAPK pathway. [Read the Full Post]